This site is intended for health professionals only!

Published on 24 July 2014

Share this story:
Twitter
LinkedIn

Selincro enters the market in Spain

Biotie, the specialised drug development company focused on products for neurodegenerative and psychiatric disorders, has announced that its partner Lundbeck has launched Selincro in Spain.
Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (>60 g/day for men, >40 g/day for women) without physical withdrawal symptoms and who do not require immediate detoxification.

Biotie, the specialised drug development company focused on products for neurodegenerative and psychiatric disorders, has announced that its partner Lundbeck has launched Selincro in Spain.
Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (>60 g/day for men, >40 g/day for women) without physical withdrawal symptoms and who do not require immediate detoxification.
According to the terms of the licence agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment of €2 million related to the market entry. Lundbeck will continue the rollout of Selincro in additional European markets during 2014.



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn